Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Carrick Therapeutics

The Oxford Cancer Trials Unit were key recruiters for our complex early development First Time in Human and initial cohort expansions oncology studies.  The work was delivered in a timely manner to a very high quality.  Dr Lord was invariably willing to provide expert disease area advice as well.  We are delighted to continue working with this team on our next study program.

Dr Stuart McIntosh, Chief Medical Officer, Carrick Therapeutics

Nucana

NuCana have worked closely with Oxford Cancer Trials unit to conduct all our first-in-human clinical studies since 2015. They are highly organised, efficient and provide exemplary care to our study patients. They’ve delivered excellent results in a timely manner, and I highly recommend this centre to any company wishing to develop a new cancer drug.

Hugh Griffith, CEO and Founder, NuCana plc

Nurix

As a company and trials sponsor our interaction with the early phase trials unit in Oxford has been very positive. They are a very engaged team, responsive and committed to delivering high quality clinical research in haematology and oncology. We have valued Professor Collins input at our investigator calls and meetings and his clinical expertise in guiding further development of our agents. He was also instrumental in helping the study to move forward as a whole in the UK by introducing other PIs to participate during startup. We look forward to a continued collaboration.

Dr Sarah Injac, Director of Clinical Development, Nurix